Ipilimumab-Based Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events With Ipilimumab Monotherapy and Combination Therapy With Nivolumab

Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP®, APHN; Brianna Hoffner, RN, MSN, APN-BC, AOCNP®


Background: Ipilimumab (Yervoy®) therapy improves outcomes in patients with resected stage III melanoma, and ipilimumab alone or combined with nivolumab (Opdivo®) does so in those with unresectable or metastatic melanoma. These immunotherapies are associated with immune-related adverse events (irAEs). With prompt recognition and appropriate management, serious sequelae or unnecessary treatment discontinuation can be prevented.

Objectives: This article presents consensus statements to guide oncology nurses in the recognition and management of irAEs associated with ipilimumab and nivolumab. 

Methods: Members of the Melanoma Nursing Initiative reviewed the current literature and clinical experience regarding nursing interventions related to irAEs associated with ipilimumab or ipilimumab and nivolumab therapy.

Findings: The care step pathways provided represent a proactive, evidence-based, and comprehensive plan to support optimal patient outcomes.

View Article @ cjon.ons.org

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles